These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 28581873)

  • 21. Management of Residual Psoriasis in Patients on Biologic Treatment.
    Haidari W; Pona A; Feldman SR
    J Drugs Dermatol; 2020 Feb; 19(2):188-194. PubMed ID: 32129969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
    Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
    Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
    Balak DMW; Carrascosa JM; Gregoriou S; Calzavara-Pinton P; Bewley A; Antunes J; Nyeland ME; Viola MG; Sawyer LM; Becla L
    J Dermatolog Treat; 2021 Nov; 32(7):701-708. PubMed ID: 31940225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
    Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
    J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
    Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
    J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
    Petersen B; Lebwohl M
    J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
    Bagel J; Nelson E; Riley C; Hetzel A
    J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions.
    Gerdes S; Krakor M; Anger T; Hutt HJ; Körber A
    Dermatology; 2017; 233(6):425-434. PubMed ID: 29502110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis.
    Amat-Samaranch V; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):423-432. PubMed ID: 32243212
    [No Abstract]   [Full Text] [Related]  

  • 30. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
    Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
    Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
    Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
    J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.
    Menter A; Gold LS; Koo J; Villumsen J; Rosén M; Lebwohl M
    Skinmed; 2017; 15(2):119-124. PubMed ID: 28528605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.
    Paul C; Bang B; Lebwohl M
    Expert Opin Pharmacother; 2017 Jan; 18(1):115-121. PubMed ID: 27936972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
    Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic.
    Takahashi H; Satoh K; Takagi A; Iizuka H
    J Dermatol; 2017 Sep; 44(9):1024-1026. PubMed ID: 28406531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam for Plaque Psoriasis in Adolescents Aged 12-17 Years.
    Abramovits W; Teng JMC; Vincent KD; Gupta AK
    Skinmed; 2020; 18(4):229-233. PubMed ID: 33032687
    [No Abstract]   [Full Text] [Related]  

  • 39. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
    Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
    J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?
    Giovene GL; Giacomelli L;
    G Ital Dermatol Venereol; 2018 Dec; 153(6):872-876. PubMed ID: 30261718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.